Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2023 - 2030
- Report ID: GVR-1-68038-051-4
- Number of Pages: 170
- Format: Electronic (PDF)
- Historical Range: 2017 - 2020
- Industry: Healthcare
Market Segmentation
- Biosimulation Product Outlook (Revenue, USD Million, 2017 - 2030)
- Software
- Services
- In-house Services
- Contract Services
- Biosimulation Application Outlook (Revenue, USD Million, 2017 - 2030)
- Drug Development
- Drug Discovery
- Others
- Biosimulation By Delivery Model (Revenue, USD Million, 2017 - 2030)
- Subscription Models
- Ownership Models
- Biosimulation End-use Outlook (Revenue, USD Million, 2017 - 2030)
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Biosimulation Regional Outlook (Revenue, USD Million, 2017 - 2030)
- North America
- North America Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- North America Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- North America Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- North America Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- U.S.
- U.S. Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- U.S. Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- U.S. Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- U.S. BiosimulationMarket, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- U.S. Biosimulation Market, By Product
- Canada
- Canada Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Canada Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Canada Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Canada Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Canada Biosimulation Market, By Product
- North America Biosimulation Market, By Product
- Europe
- Europe Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Europe Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Europe Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Europe Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- U.K.
- U.K. Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- U.K. Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- U.K. Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- U.K. Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- U.K. Biosimulation Market, By Product
- Germany
- Germany Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Germany Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Germany Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Germany Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Germany Biosimulation Market, By Product
- France
- France Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- France Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- France Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- France Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- France Biosimulation Market, By Product
- Italy
- Italy Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Italy Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Italy Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Italy Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Italy Biosimulation Market, By Product
- Spain
- Spain Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Spain Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Spain Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Spain Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Spain Biosimulation Market, By Product
- Norway
- Norway Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Norway Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Norway Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Norway Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Norway Biosimulation Market, By Product
- Denmark
- Denmark Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Denmark Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Denmark Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Denmark Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Denmark Biosimulation Market, By Product
- Sweden
- Sweden Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Sweden Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Sweden Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Sweden Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Sweden Biosimulation Market, By Product
- Europe Biosimulation Market, By Product
- Asia Pacific
- Asia Pacific Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Asia Pacific Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Asia Pacific Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Asia Pacific Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Japan
- Japan Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Japan Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Japan Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Japan Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Japan Biosimulation Market, By Product
- China
- China Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- China Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- China Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- China Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- China Biosimulation Market, By Product
- India
- India Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- India Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- India Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- India Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- India Biosimulation Market, By Product
- South Korea
- South Korea Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- South Korea Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- South Korea Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- South Korea Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- South Korea Biosimulation Market, By Product
- Thailand
- Thailand Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Thailand Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Thailand Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Thailand Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Thailand Biosimulation Market, By Product
- Australia
- Australia Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Australia Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Australia Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Australia Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Australia Biosimulation Market, By Product
- Asia Pacific Biosimulation Market, By Product
- Latin America
- Latin America Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Latin America Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Latin America Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Latin America Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Mexico
- Mexico Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Mexico Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Mexico Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Mexico Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Brazil
- Brazil Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Brazil Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Other
- Brazil Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Brazil Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Brazil Biosimulation Market, By Product
- Argentina
- Argentina Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Argentina Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Other
- Argentina Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Argentina Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Argentina Biosimulation Market, By Product
- Latin America Biosimulation Market, By Product
- MEA
- MEA Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- MEA Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- MEA Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- MEA Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- South Africa
- South Africa Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- South Africa Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- South Africa Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- South Africa Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- South Africa Biosimulation Market, By Product
- Saudi Arabia
- Saudi Arabia Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Saudi Arabia Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Saudi Arabia Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Saudi Arabia Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Saudi Arabia Biosimulation Market, By Product
- UAE
- UAE Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- UAE Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- UAE Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- UAE Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- UAE Biosimulation Market, By Product
- Kuwait
- Kuwait Biosimulation Market, By Product
- Software
- Services
- In-house Services
- Contract Services
- Kuwait Biosimulation Market, By Application
- Drug Development
- Drug Discovery
- Others
- Kuwait Biosimulation Market, By Delivery Model
- Subscription Models
- Ownership Models
- Kuwait Biosimulation Market, By End-use
- Pharmaceutical & Biotechnology Companies
- CROs
- Regulatory Authorities
- Academic Research Institutions
- Kuwait Biosimulation Market, By Product
- MEA Biosimulation Market, By Product
- North America
Biosimulation Market Dynamics
Drivers: Increasing Adoption Of Physiologically Based Pharmacokinetic Modeling In Regulatory Approval Process Of Drugs
Simulation of drug disposition and pharmacokinetic prediction has evolved as an important tool in regulatory approvals. PBPK predictions are beneficial while submitting new drug applications for filling in the unknown clinical gaps during the evaluation process of a breakthrough therapy drug. The U.S. Food and Drug Administration recently made available a guidance document regarding the concerned format and content of PBPK data in regulatory submissions. It suggested using PBPK modeling in hepatic impairment studies and drug-drug interactions assessment. Similarly, the European Medicines Agency released its own guidelines for using PBPK modeling for research purposes. It mandated a detailed report of the model, which included an overview of the model building process, sensitivity analysis, drug-specific parameters, and a discussion on the regulatory impact of the modeling submitted along with the results and other relevant information.
Growing Number Of Relapse Cases Due To Increasing Drug Resistance
There has been an increase in the number of drug relapse cases due to acquired drug resistance in conditions such as cancer, tuberculosis, and other bacterial infection, which is anticipated to drive the clinical urgency to adopt biosimulation to initiate the development of a new generation of drugs. Biosimulation helps gain better insights into the mechanism of drug resistance and aids in the identification of therapies with high potency & lower susceptibility to drug resistance. Also, the adoption of prolonged therapies in cases such as diabetes can result in poor patient adherence and the formation of drug-resistant bacteria, which may hinder the overall treatment regime. The abovementioned scenario is believed to be intercepted through the adoption of biosimulation software, shorten the therapy duration, and simplify the overall process.
Restraint: Lack Of Standardization
Biosimulation utilizes different tools, languages, and models for processing & collecting different features of biological processes. The present modeling techniques do not capture the fundamental semantics of biosimulation models to support composing, building, reusing, and merging of different, complex models. The regulatory authorities are yet to normalize the use of biosimulation or in silico technologies in the drug development or discovery process. Recent advancements in computational biology ease out the process of building complex models and managing biomedical researchers. However, as their simulations and models expand in terms of complexity, researchers find it more problematic to manage, edit, & share their models. This problem becomes severe due to the lack of scalable criteria for model reuse and representation. As a result, many researchers are unable to build and share new simulation models upon formerly coded models. Moreover, the lack of standardization of these software tools also plays a key role in restricting researchers and healthcare professionals from learning new models, as every software differs in a user interface.
What Does This Report Include?
This section will provide insights into the contents included in this biosimulation market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Biosimulation market qualitative analysis
-
Industry overview
-
Industry trends
-
Market drivers and restraints
-
Market size
-
Growth prospects
-
Porter’s analysis
-
PESTEL analysis
-
Key market opportunities prioritized
-
Competitive landscape
-
Company overview
-
Financial performance
-
Product benchmarking
-
Latest strategic developments
-
Biosimulation market quantitative analysis
-
Market size, estimates, and forecast from 2017 to 2030
-
Market estimates and forecast for product segments up to 2030
-
Regional market size and forecast for product segments up to 2030
-
Market estimates and forecast for application segments up to 2030
-
Regional market size and forecast for application segments up to 2030
-
Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
